Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

Inclusion Criteria

• •Male or female patients aged between 45-75 years old.
• •Clinical diagnosis of PD according to UK Brain Bank Criteria.
• •3 months of clinical stability before study enrolment.
• •Anti-parkinsonian medication is fixed for at least 3 months prior to study entry.
• •Male or female patients 18 years old or older.
• •Diagnosis of RR-MS according to McDonald criteria.
• •Expanded Disability Status Scale(EDSS) lower or equal to 5.5.
• •Stable disease for at least 30 days prior to study entry.
• •Stable disease-modifying therapy for at least 3 months prior to study entry.
• •No changes in drug treatment during 6 months-study treatment.
• •Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project.
• •Written informed consent.
• •Eligible patients are those clinically stable;
• •Age range from 1 to 10, between 5 and 30 kg.
• •Patients not involved in other clinical trials.